The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Healthcare resource utilization (HCRU) and costs for patients (pts) with metastatic renal cell carcinoma (mRCC) receiving first-line (LOT1) pembrolizumab plus axitinib (P+A) or ipilimumab plus nivolumab (I+N).
 
Neil J. Shah
Consulting or Advisory Role - Merck Sharp & Dohme Corp.
Research Funding - Aravive (Inst)
Travel, Accommodations, Expenses - Merck
 
Reshma Shinde
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Kristin Moore
Employment - Optum/UnitedHealth Group
 
Amy Sainski-Nguyen
Employment - Optum/UnitedHealth Group
 
Lisa Le
Employment - Optum/UnitedHealth Group
Stock and Other Ownership Interests - United Health Group
 
Feng Cao
Employment - OptumInsight
Stock and Other Ownership Interests - UnitedHealthcare
 
Rui Song
Employment - Optum/UnitedHealth Group
Stock and Other Ownership Interests - United Health Group
 
Puneet Singhal
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Robert J. Motzer
Consulting or Advisory Role - AstraZeneca; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Genentech/Roche; Incyte; Lilly; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb